In sum, our clinical data support the future use of CmPn members’ expression data, confirmed with AFP, as potential prognostic biomarkers for distinguishing between primary subtypes of liver cancer and evaluating tumor recurrence in patients. This evidence concerns the gene AFP and liver cancer.